How does Bio-Techne (TECH) make money?

Bio-Techne (TECH) generates revenue primarily from Consumables, which accounted for 88.1% of total revenue in TTM through Q1 2026. The company reported $1.21B in revenue and converted 9% of it into net profit, equivalent to roughly $109.57M in net income — what's left after the cost of revenue, operating expenses, interest, and income taxes.

What is the gross profit margin of Bio-Techne (TECH)?

Bio-Techne (TECH) reported a gross profit margin of 65% in TTM through Q1 2026, equivalent to $786.49M in gross profit on $1.21B in revenue. Gross margin measures how much of each dollar of revenue remains after the direct cost of producing or delivering the product — a higher figure typically signals pricing power, scale, or a less capital-intensive business model.

What is the operating profit margin of Bio-Techne (TECH)?

Bio-Techne (TECH) reported an operating profit margin of 12.7% in TTM through Q1 2026, equivalent to $153.75M in operating income. Operating margin captures profitability after research & development, sales & marketing, and general & administrative expenses — but before interest, taxes, and one-off items — and is the cleanest single read on the underlying business's efficiency.

What is the net profit margin of Bio-Techne (TECH)?

Bio-Techne (TECH) reported a net profit margin of 9% in TTM through Q1 2026, equivalent to $109.57M in net income. Net margin is the bottom-line share of revenue that survives every expense — operating costs, interest, and income taxes — and is the figure that flows directly into earnings per share.

Is Bio-Techne (TECH) profitable?

Yes. Bio-Techne (TECH) reported $109.57M in net income for TTM through Q1 2026, with a net profit margin of 9%. The company earned more from its operations than it paid out in costs, interest, and income taxes, leaving positive earnings on the bottom line.

How much does Bio-Techne (TECH) invest in research and development?

Bio-Techne (TECH) invested $96.85M in research and development during TTM through Q1 2026, roughly 8.0% of total revenue. R&D spending funds the company's future product pipeline and is expensed in full on the income statement rather than capitalised, which makes the operating margin sensitive to how aggressively management chooses to reinvest in innovation.

How much does Bio-Techne (TECH) spend on capital expenditures?

Bio-Techne (TECH) spent $25.26M on capital expenditures (CapEx) during TTM through Q1 2026, roughly 2.1% of total revenue. CapEx represents long-lived investment in property, equipment, data centres, and other physical infrastructure, and is subtracted from operating cash flow to arrive at free cash flow.

How much free cash flow does Bio-Techne (TECH) generate?

Bio-Techne (TECH) generated $269.60M in free cash flow during TTM through Q1 2026, a free-cash-flow margin of 22.3%. Free cash flow is the cash left after capital expenditures and represents the discretionary pool the company can use to pay dividends, repurchase shares, repay debt, or fund acquisitions without raising external capital.

What is the effective tax rate of Bio-Techne (TECH)?

Bio-Techne (TECH) had an effective tax rate of 25.5% in TTM through Q1 2026. The effective rate is the actual share of pre-tax income paid as income taxes and can differ materially from the statutory rate due to foreign earnings mix, tax credits (such as R&D), share-based compensation deductions, and one-off discrete items.

What are the main business segments of Bio-Techne (TECH)?

Bio-Techne (TECH) reports revenue across 3 reportable product segments, led by Consumables at 88.1% of total revenue in TTM through Q1 2026. See the revenue-by-segment table on this page for the full breakdown and how each segment feeds into the income-statement waterfall above.

Where does Bio-Techne (TECH) generate most of its revenue?

U S is the largest geographic market for Bio-Techne (TECH), accounting for 53.3% of revenue in the most recent annual filing. The complete regional split — including international markets and any Rest-of-World rollup — is shown in the revenue-by-geography table on this page.

How Bio-Techne Makes Money: 2026 Visual Revenue Map

Bio-Techne (TECH) Income Statement Flow — TTM through Q1 2026

Calculated from the four most recent reported quarters, ending March 31, 2026 (reported May 6, 2026).

Bio-Techne (TECH) Revenue by Product Segment — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported segments changed mid-year.

Revenue contribution by product segment for Bio-Techne (TECH) in TTM through Q1 2026.
Segment	Revenue (USD)	% of total
Consumables	$1.07B	88.1%
Instruments	$117.81M	9.7%
Royalty	$26.87M	2.2%
Total	$1.21B	100%

Consumables$1.07B
Instruments$117.81M
Royalty$26.87M
Total$1.21B

Bio-Techne (TECH) Revenue by Geography — TTM through Q1 2026

Aggregated from the four quarterly disclosures behind this TTM. Minor differences vs the company's annual filing can occur if reported regions changed mid-year.

Revenue contribution by geographic region for Bio-Techne (TECH), TTM through Q1 2026
Region	Revenue (USD)	% of total
U S	$645.66M	53.3%
Europe	$284.28M	23.5%
C N	$104.05M	8.6%
APAC, excluding Greater China	$82.59M	6.8%
UNITED KINGDOM	$56.61M	4.7%
Rest Of World	$37.61M	3.1%
Total	$1.21B	100%

U S
Europe
C N
APAC, excluding Greater China
UNITED KINGDOM
Rest Of World
Total

Revenue Breakdown — TTM through Q1 2026

In TTM through Q1 2026, Bio-Techne (TECH) reports revenue across 3 operating segments; the largest segment was Consumables at 88.1%, followed by Instruments (9.7%) and Royalty (2.2%). Separately, by end-market geography, U S accounted for 53.3% of revenue, followed by Europe (23.5%) and C N (8.6%).

Frequently asked questions

Data & methodology

Bio-Techne (TECH) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview

TECH Overview

Counters

Income Statement

Cash Flow

Capital Return

Forecast & Valuation